Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. leiter's cambrian park drugs, inc.,
483
•leiter's cambrian park drugs, inc., •March 6, 2014

leiter's cambrian park drugs, inc., – FDA 483, Mar 6, 2014

Record Details

The FDA inspection revealed significant deficiencies in the manufacturing and quality control of Brilliant Blue G D2O 0.025% and other sterile drug products. The firm failed to ensure sterility and pyrogen-free status through adequate testing. Sterility testing by a contract lab lacked method suitability data and did not meet USP <71> requirements for sampling/method suitability. No endotoxin release specification was established, and products were released regardless of endotoxin results.

Aseptic process validation was inadequate. One operator for the Baxa Repeater Pump, used for Brilliant Blue G D2O 0.025%, was not qualified per SOP. Media fill records lacked documentation of the hood used and the number of operators present. Environmental monitoring procedures were not followed, with surface and fingertip samples not taken on multiple dates due to lack of supplies, even when Brilliant Blue G D2O 0.025% was filled. Personnel were observed with makeup in the cleanroom, violating garb SOPs.

The firm used expired raw material (Sodium Phosphate Monobasic Monohydrate) for six lots of Brilliant Blue G D2O 0.025% and failed to conduct a comprehensive investigation into its impact. Finished product potency testing was never performed for 14 lots of Brilliant Blue G D2O 0.025%. There was no stability testing program to justify the 180-day Beyond Use Date for Brilliant Blue G D

Company
leiter's cambrian park drugs, inc.,
Inspection date
March 6, 2014
Product type
Drugs
Office
San Francisco District Office
Person
  • Henry K. Lau (Founder)
View Company Profile

ID · af17a474-8971-4054-983a-141cec0efaf6

Violation Codes9
21 U.S.C. 324(a)(4)21 CFR 21021 CFR 211FD&C Act 801(a)(3)21 CFR 331(c)21 CFR 521 CFR 7121 CFR 10021 CFR 200

Full citation text and observation details available on the Dashboard.

Other documents for leiter's cambrian park drugs, inc.,
  • 483 - 2013-11-05November 5, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore leiter's cambrian park drugs, inc.,
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.